-
1دورية أكاديمية
المؤلفون: Evangelia Vlachou, Burles Avner Johnson, David McConkey, Yuezhou Jing, Andres Matoso, Noah M. Hahn, Jean Hoffman-Censits
المصدر: Frontiers in Oncology, Vol 14 (2024)
مصطلحات موضوعية: advanced/metastatic urothelial cancer, bladder cancer, cutaneous adverse events, disease response, enfortumab vedotin (EV), overall survival (OS), Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
وصف الملف: electronic resource
العلاقة: https://www.frontiersin.org/articles/10.3389/fonc.2024.1377842/fullTest; https://doaj.org/toc/2234-943XTest
-
2دورية أكاديمية
المؤلفون: Sara Mokbel, Giuilia Baciarello, Pernelle Lavaud, Aurelius Omlin, Fabio Calabrò, Richard Cathomas, Stefanie Aeppli, Pauline Parent, Patrizia Giannatempo, Kira-Lee Koster, Naara Appel, Philippe Gonnet, Gesuino Angius, Petros Tsantoulis, Hendrick-Tobias Arkenau, Carlo Cattrini, Carlo Messina, Jean Zeghondy, Cristina Morelli, Yohann Loriot, Vincenzo Formica, Anna Patrikidou
المصدر: Cancers, Vol 16, Iss 8, p 1465 (2024)
مصطلحات موضوعية: immune checkpoint inhibitors, advanced/metastatic urothelial cancer, inflammatory markers, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
وصف الملف: electronic resource
-
3دورية أكاديمية
المؤلفون: Vlachou, Evangelia, Johnson, Burles Avner, McConkey, David, Jing, Yuezhou, Matoso, Andres, Hahn, Noah M, Hoffman-Censits, Jean
المصدر: Front Oncol ; ISSN:2234-943X ; Volume:14
مصطلحات موضوعية: advanced/metastatic urothelial cancer, bladder cancer, cutaneous adverse events, disease response, enfortumab vedotin (EV), overall survival (OS), progression-free survival (PFS), skin toxicity
العلاقة: https://doi.org/10.3389/fonc.2024.1377842Test; https://pubmed.ncbi.nlm.nih.gov/38933451Test; https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11199536Test/
الإتاحة: https://doi.org/10.3389/fonc.2024.1377842Test
https://pubmed.ncbi.nlm.nih.gov/38933451Test
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11199536Test/